SEC Form 4 · accession 0000899243-18-022461
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara K Finck
Officer — Chief Medical Officer
Period of report
Aug 13, 2018
Accepted (ET)
Aug 15, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Aug 13, 2018 | M | 1,760 | $1.42 | A | 38,803 | D | |
| Common Stock, $0.0001 par valueF2 | Aug 13, 2018 | S | 1,760 | $19.0227 | D | 37,043 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.42 | Aug 13, 2018 | M | 1,760 | D | — | Nov 21, 2023 | Common Stock | 1,760 | 84,701 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- F2The transaction was executed in multiple trades in prices ranging from $18.80 to $19.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F3The shares underlying this option are fully vested and exercisable as of the date hereof.